Katsutoshi Furukawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katsutoshi Furukawa has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
Hiroyuki Arai
Department of Geriatrics and Gerontology; Institute of Development, Aging and Cancer, Tohoku University; Sendai Japan
15 shared publications- Nobuyuki Okamura
Tohoku Medical and Pharmaceutical University, Sendai Japan
9 shared publications - Kazuhiko Yanai
Dept Pharmacol Tohoku Univ Grad Sch Med
7 shared publications Naoki Tomita
Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Japan
5 shared publicationsAiko Ishiki
Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Japan
4 shared publications- Yukitsuka Kudo
Innovation of New Biomedical Engineering Center, Tohoku University, Sendai, Japan
4 shared publications
Latest Publications
- Open Access
- 1 June 2019
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2019 (6) , omz047
Development of geriatric syndromes after taking countermeasures for polypharmacy: an overlooked issue of quitting semiregular single-dose medicine
We report a case of an elderly woman on polypharmacy who developed appetite loss, general fatigue and muscle weakness mainly from secondary adrenal insufficiency caused by quitting one semiregular single-dose medicine. Because the degree of insufficiency was mild, her symptoms were eliminated after some time without additional treatment. The present case includes important lessons related to medication management in elderly patients. Additionally, the present case also warns us to be cautious while diagnosing geriatric syndromes as a part of the physiological aging process or additional disease symptoms. Drug-induced geriatric syndrome from quitting semiregular-use drugs should be investigated in future studies.
- 1 June 2019
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2019 (6) , omz047
Open AccessDevelopment of geriatric syndromes after taking countermeasures for polypharmacy: an overlooked issue of quitting semiregular single-dose medicine
We report a case of an elderly woman on polypharmacy who developed appetite loss, general fatigue and muscle weakness mainly from secondary adrenal insufficiency caused by quitting one semiregular single-dose medicine. Because the degree of insufficiency was mild, her symptoms were eliminated after some time without additional treatment. The present case includes important lessons related to medication management in elderly patients. Additionally, the present case also warns us to be cautious while diagnosing geriatric syndromes as a part of the physiological aging process or additional disease symptoms. Drug-induced geriatric syndrome from quitting semiregular-use drugs should be investigated in future studies.
- Open Access
- 29 June 2018
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 6 (1) , 1-10
Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy
Recent positron emission tomography (PET) studies have demonstrated the accumulation of tau PET tracer in the affected region of progressive supranuclear palsy (PSP) cases. To confirm the binding target of radiotracer in PSP, we performed an imaging-pathology correlation study in two autopsy-confirmed PSP patients who underwent [18F]THK5351 PET before death. One patient with PSP Richardson syndrome showed elevated tracer retention in the globus pallidus and midbrain. In a patient with PSP-progressive nonfluent aphasia, [18F]THK5351 retention also was observed in the cortical areas, particularly the temporal cortex. Neuropathological examination confirmed PSP in both patients. Regional [18F]THK5351 standardized uptake value ratio (SUVR) in antemortem PET was significantly correlated with monoamine oxidase-B (MAO-B) level, reactive astrocytes density, and tau pathology at postmortem examination. In in vitro autoradiography, specific THK5351 binding was detected in the area of antemortem [18F]THK5351 retention, and binding was blocked completely by a reversible selective MAO-B inhibitor, lazabemide, in brain samples from these patients. In conclusion, [18F]THK5351 PET signals reflect MAO-B expressing reactive astrocytes, which may be associated with tau accumulation in PSP.
- 29 June 2018
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 6 (1) , 1-10
Open AccessNeuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy
Recent positron emission tomography (PET) studies have demonstrated the accumulation of tau PET tracer in the affected region of progressive supranuclear palsy (PSP) cases. To confirm the binding target of radiotracer in PSP, we performed an imaging-pathology correlation study in two autopsy-confirmed PSP patients who underwent [18F]THK5351 PET before death. One patient with PSP Richardson syndrome showed elevated tracer retention in the globus pallidus and midbrain. In a patient with PSP-progressive nonfluent aphasia, [18F]THK5351 retention also was observed in the cortical areas, particularly the temporal cortex. Neuropathological examination confirmed PSP in both patients. Regional [18F]THK5351 standardized uptake value ratio (SUVR) in antemortem PET was significantly correlated with monoamine oxidase-B (MAO-B) level, reactive astrocytes density, and tau pathology at postmortem examination. In in vitro autoradiography, specific THK5351 binding was detected in the area of antemortem [18F]THK5351 retention, and binding was blocked completely by a reversible selective MAO-B inhibitor, lazabemide, in brain samples from these patients. In conclusion, [18F]THK5351 PET signals reflect MAO-B expressing reactive astrocytes, which may be associated with tau accumulation in PSP.
- 15 May 2017
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 17 (5) , 852-854
Reduced brain-derived neurotrophic factor is associated with cognitive dysfunction in patients with chronic heart failure
- 15 May 2017
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 17 (5) , 852-854
Reduced brain-derived neurotrophic factor is associated with cognitive dysfunction in patients with chronic heart failure
- 12 April 2017
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 17 (4) , 663-664
Establishment of a new medical school in the Tohoku region after the Great East Japan Earthquake
- 12 April 2017
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 17 (4) , 663-664
Establishment of a new medical school in the Tohoku region after the Great East Japan Earthquake
- 31 October 2016
- Published by Wiley in European Journal of Neurology
- Vol. 24 (1) , 130-136
Tau imaging with [18F]THK‐5351 in progressive supranuclear palsy
Background and purpose: Visualization of pathogenic protein aggregates is crucial to elucidate pathomechanisms and to make an accurate diagnosis in many neurodegenerative conditions. Aggregates of the microtubule‐binding protein, tau, are one of the most important pathogenic molecules in neurodegenerative disorders. Progressive supranuclear palsy (PSP) is characterized by the deposition of tau proteins in some specific area such as the basal ganglia and brainstem. We tried to detect tau lesions in the brains of living patients with PSP with a novel positron emission tomography (PET) tracer, [18F]THK‐5351, which we have recently developed.Methods: Paraffin‐embedded brain sections of the patients with PSP were used for autoradiography with [3H]THK‐5351 and immunohistochemistry. Nine healthy controls, 13 patients with Alzheimer's disease and three patients with PSP participated in this PET study with [18F]THK‐5351. To detect amyloid‐β deposition, PET imaging with Pittsburgh compound B was also performed.Results: Autoradiography in the brain sections of patients with PSP demonstrated [3H]THK‐5351 binding to tau deposits with a high selectivity. Although patients with PSP exhibited no remarkable [18F]THK‐5351 retention in the temporal cortex, significantly higher tracer retention was observed in the globus pallidus and midbrain. In contrast, amyloid imaging with Pittsburgh compound B showed no remarkable accumulation in the cerebral cortex of PSP.Conclusions: We conclude that [18F]THK‐5351 PET can potentially be used to detect the regional brain distribution of tau lesions in PSP, thereby facilitating the differential diagnosis of neurodegenerative disorders associated with tau protein.
- 31 October 2016
- Published by Wiley in European Journal of Neurology
- Vol. 24 (1) , 130-136
Tau imaging with [18F]THK‐5351 in progressive supranuclear palsy
Background and purpose: Visualization of pathogenic protein aggregates is crucial to elucidate pathomechanisms and to make an accurate diagnosis in many neurodegenerative conditions. Aggregates of the microtubule‐binding protein, tau, are one of the most important pathogenic molecules in neurodegenerative disorders. Progressive supranuclear palsy (PSP) is characterized by the deposition of tau proteins in some specific area such as the basal ganglia and brainstem. We tried to detect tau lesions in the brains of living patients with PSP with a novel positron emission tomography (PET) tracer, [18F]THK‐5351, which we have recently developed.Methods: Paraffin‐embedded brain sections of the patients with PSP were used for autoradiography with [3H]THK‐5351 and immunohistochemistry. Nine healthy controls, 13 patients with Alzheimer's disease and three patients with PSP participated in this PET study with [18F]THK‐5351. To detect amyloid‐β deposition, PET imaging with Pittsburgh compound B was also performed.Results: Autoradiography in the brain sections of patients with PSP demonstrated [3H]THK‐5351 binding to tau deposits with a high selectivity. Although patients with PSP exhibited no remarkable [18F]THK‐5351 retention in the temporal cortex, significantly higher tracer retention was observed in the globus pallidus and midbrain. In contrast, amyloid imaging with Pittsburgh compound B showed no remarkable accumulation in the cerebral cortex of PSP.Conclusions: We conclude that [18F]THK‐5351 PET can potentially be used to detect the regional brain distribution of tau lesions in PSP, thereby facilitating the differential diagnosis of neurodegenerative disorders associated with tau protein.
- 1 September 2016
- Published by Elsevier in Ageing Research Reviews
- Vol. 30, 1-3
Introduction and overview of the special issue “Brain imaging and aging”: The new era of neuroimaging in aging research
- 1 September 2016
- Published by Elsevier in Ageing Research Reviews
- Vol. 30, 1-3
Introduction and overview of the special issue “Brain imaging and aging”: The new era of neuroimaging in aging research
- 1 March 2016
- Vol. 74 (3) , 411-6
[The trend of developing new disease-modifying drugs in Alzheimer's disease].
Development of symptomatic treatment of Alzheimer s disease by cholinesterase inhibitors like donepezil was successful. However, it is a disappointment that development of disease-modifying drugs such as anti-amyloid drug based on amyloid-cascade theory has been interrupted or unsuccessful. Therefore, we have to be more cautious regarding inclusion criteria for clinical trials of new drugs. We agree that potentially curative drugs should be started before symptoms begin as a preemptive therapy or prevention trial. The concept of personalized medicine also is important when ApoE4-related amyloid reducing therapy is considered. Unfortunately, Japanese-ADNI has suffered a setback since 2014. However, Ministry of Health, Labour and Welfare gave a final remark that there was nothing wrong in the data managing process in the J-ADNI data center. We should pay more attention to worldwide challenges of speeding up new drug development.
- 1 March 2016
- Vol. 74 (3) , 411-6
[The trend of developing new disease-modifying drugs in Alzheimer's disease].
Development of symptomatic treatment of Alzheimer s disease by cholinesterase inhibitors like donepezil was successful. However, it is a disappointment that development of disease-modifying drugs such as anti-amyloid drug based on amyloid-cascade theory has been interrupted or unsuccessful. Therefore, we have to be more cautious regarding inclusion criteria for clinical trials of new drugs. We agree that potentially curative drugs should be started before symptoms begin as a preemptive therapy or prevention trial. The concept of personalized medicine also is important when ApoE4-related amyloid reducing therapy is considered. Unfortunately, Japanese-ADNI has suffered a setback since 2014. However, Ministry of Health, Labour and Welfare gave a final remark that there was nothing wrong in the data managing process in the J-ADNI data center. We should pay more attention to worldwide challenges of speeding up new drug development.
- 1 March 2016
- Vol. 74 (3) , 519-22
[What we did and learnt in the care of the patients with dementia after the Great East Japan Earthquake in 2011].
Northeast Japan experienced an earthquake of magnitude 9.0, followed by enormous tsunamis on March 11th 2011. "The Great East Japan Earthquake" greatly affected health conditions of elderly people. Our group has reported that cognitive functions of elders were negatively influenced by this disaster. Several reasons of the cognitive deterioration could be considered such as (1) changes in the living circumstance, (2) loss of families, relatives, and friends, (3) loss of their daily activities such as farming and fishing, and (4) isolation from families and neighbors. We are now performing some anti-dementia programs including exercise, diet, and management for lifestyle-related disorders to prevent dementia.
- 1 March 2016
- Vol. 74 (3) , 519-22
[What we did and learnt in the care of the patients with dementia after the Great East Japan Earthquake in 2011].
Northeast Japan experienced an earthquake of magnitude 9.0, followed by enormous tsunamis on March 11th 2011. "The Great East Japan Earthquake" greatly affected health conditions of elderly people. Our group has reported that cognitive functions of elders were negatively influenced by this disaster. Several reasons of the cognitive deterioration could be considered such as (1) changes in the living circumstance, (2) loss of families, relatives, and friends, (3) loss of their daily activities such as farming and fishing, and (4) isolation from families and neighbors. We are now performing some anti-dementia programs including exercise, diet, and management for lifestyle-related disorders to prevent dementia.
- Open Access
- 13 January 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (1) , e0147025
Changes in Cognitive Functions in the Elderly Living in Temporary Housing after the Great East Japan Earthquake
On March 11, 2011, Japan experienced an earthquake of magnitude 9.0 and subsequent enormous tsunamis. This disaster destroyed many coastal cities and caused nearly 20,000 casualties. In the aftermath of the disaster, many tsunami survivors who lost their homes were forced to live in small temporary apartments. Although all tsunami survivors were at risk of deteriorating health, the elderly people were particularly at a great risk with regard to not only their physical health but also their mental health. In the present study, we performed a longitudinal cohort study to investigate and analyze health conditions and cognitive functions at 28, 32, and 42 months after the disaster in the elderly people who were forced to reside in temporary apartments in Kesennuma, a city severely damaged by the tsunamis. The ratio of people considered to be cognitively impaired significantly increased during the research period. On the other hand, the mean scores of the Kessler Psychological Distress Scale-6 and Athens Insomnia Scale improved based on the comparison between the data at 24 and 42 months. The multiple logistic regression analysis revealed that frequency of “out-of-home activities” and “walking duration” were independently associated with an increase in the ratio of people with cognitive impairment. We concluded that the elderly people living in temporary apartments were at a high risk of cognitive impairment and “out-of-home activities” and “walking” could possibly maintain the stability of cognitive functions.
- 13 January 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (1) , e0147025
Open AccessChanges in Cognitive Functions in the Elderly Living in Temporary Housing after the Great East Japan Earthquake
On March 11, 2011, Japan experienced an earthquake of magnitude 9.0 and subsequent enormous tsunamis. This disaster destroyed many coastal cities and caused nearly 20,000 casualties. In the aftermath of the disaster, many tsunami survivors who lost their homes were forced to live in small temporary apartments. Although all tsunami survivors were at risk of deteriorating health, the elderly people were particularly at a great risk with regard to not only their physical health but also their mental health. In the present study, we performed a longitudinal cohort study to investigate and analyze health conditions and cognitive functions at 28, 32, and 42 months after the disaster in the elderly people who were forced to reside in temporary apartments in Kesennuma, a city severely damaged by the tsunamis. The ratio of people considered to be cognitively impaired significantly increased during the research period. On the other hand, the mean scores of the Kessler Psychological Distress Scale-6 and Athens Insomnia Scale improved based on the comparison between the data at 24 and 42 months. The multiple logistic regression analysis revealed that frequency of “out-of-home activities” and “walking duration” were independently associated with an increase in the ratio of people with cognitive impairment. We concluded that the elderly people living in temporary apartments were at a high risk of cognitive impairment and “out-of-home activities” and “walking” could possibly maintain the stability of cognitive functions.
- 29 December 2015
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 17 (2) , 211-218
Randomized double‐blind placebo‐controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease
Aim Yokukansan (YKS), a traditional herbal medicine, has been used to treat behavioral and psychological symptoms of dementia (BPSD). The present study is the first double‐blind, randomized, placebo‐controlled trial to determine the efficacy and safety of YKS for the treatment of BPSD in Alzheimer's disease (AD). Methods A total of 22 sites consisting of clinics, hospitals and nursing homes participated. A total of 145 patients with AD were randomized. Active YKS (7.5 g/day) and placebo were supplied to 75 and 70 participants, respectively. The primary outcome measure was the 4‐week change in total score of the Neuropsychiatric Inventory Brief Questionnaire Form (NPI‐Q), an instrument that evaluates BPSD. Secondary outcome measures included 12‐week changes in NPI‐Q scores, changes in NPI‐Q subcategory scores and total scores of the Mini‐Mental‐State Examination. Results Four‐week changes in NPI‐Q total scores did not differ significantly between the treatment and placebo groups. There were also no significant differences between groups in 12‐week changes in total NPI‐Q scores, NPI‐Q subcategory scores or total Mini‐Mental‐State Examination scores. However, a subgroup with fewer than 20 points on the Mini‐Mental‐State Examination at baseline showed a greater decrease in “agitation/aggression” score in the YKS group than in the placebo group (P = 0.007). No serious adverse effects were observed during the study. Conclusions Our data did not reach statistical significance regarding the efficacy of YKS against BPSD; however, YKS improves some symptoms including “agitation/aggression” and “hallucinations” with low frequencies of adverse events. Geriatr Gerontol Int 2017; 17: 211–218
- 29 December 2015
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 17 (2) , 211-218
Randomized double‐blind placebo‐controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease
Aim Yokukansan (YKS), a traditional herbal medicine, has been used to treat behavioral and psychological symptoms of dementia (BPSD). The present study is the first double‐blind, randomized, placebo‐controlled trial to determine the efficacy and safety of YKS for the treatment of BPSD in Alzheimer's disease (AD). Methods A total of 22 sites consisting of clinics, hospitals and nursing homes participated. A total of 145 patients with AD were randomized. Active YKS (7.5 g/day) and placebo were supplied to 75 and 70 participants, respectively. The primary outcome measure was the 4‐week change in total score of the Neuropsychiatric Inventory Brief Questionnaire Form (NPI‐Q), an instrument that evaluates BPSD. Secondary outcome measures included 12‐week changes in NPI‐Q scores, changes in NPI‐Q subcategory scores and total scores of the Mini‐Mental‐State Examination. Results Four‐week changes in NPI‐Q total scores did not differ significantly between the treatment and placebo groups. There were also no significant differences between groups in 12‐week changes in total NPI‐Q scores, NPI‐Q subcategory scores or total Mini‐Mental‐State Examination scores. However, a subgroup with fewer than 20 points on the Mini‐Mental‐State Examination at baseline showed a greater decrease in “agitation/aggression” score in the YKS group than in the placebo group (P = 0.007). No serious adverse effects were observed during the study. Conclusions Our data did not reach statistical significance regarding the efficacy of YKS against BPSD; however, YKS improves some symptoms including “agitation/aggression” and “hallucinations” with low frequencies of adverse events. Geriatr Gerontol Int 2017; 17: 211–218